IXJ
iShares Global Healthcare ETF · PSE
- Category Equity
- Expense Ratio 0.42%
- Listing Date Nov 16, 2001
- Volume 91,880.0
- Market Cap (AUM) $4,055.62M
Performance
+3.55%
1W
+4.25%
1M
+2.1%
3M
+12.86%
6M
+8.26%
YTD
+13.47%
1Y
Top Holdings
-
Name
Symbol%Assets
- Eli Lilly and CompanyLLY8.72%
- UnitedHealth Group IncorporatedUNH6.12%
- Novo Nordisk A/S Class BNOVO.B5.95%
- Johnson & JohnsonJNJ4.43%
- Merck & Co., Inc.MRK4.31%
- AbbVie, Inc.ABBV3.84%
- AstraZeneca PLCAZN3.26%
- Thermo Fisher Scientific Inc.TMO2.93%
- Novartis AGNOVN2.88%
- Roche Holding Ltd Dividend Right Cert.ROG2.43%
Technical Analysis of IXJ 2024-05-31
Overview:
In analyzing the technical indicators for IXJ over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key aspects, we aim to offer valuable insights and recommendations for potential inv...
Recent News & Updates
- 2017-03-13 19:36
Johnson & Johnsons Pharmaceuticals Segment(Marketrealist)
- 2017-03-01 18:37
How Gileads Other Products Fared in 2016(Marketrealist)
- 2017-02-27 20:07
- 2017-02-24 03:53
Pfizers Valuation after Its 4Q16 Earnings Release(Marketrealist)
- 2017-02-23 20:07
Eli Lilly & Co.s Endocrine Franchise(Marketrealist)
- 2017-01-30 20:08
Analyzing Merck & Co.s Revenue Estimates in 4Q16(Marketrealist)
- 2017-01-30 18:37
Opdivo: Bristol-Myers Squibbs Blockbuster Oncology Drug(Marketrealist)
- 2017-01-29 20:06
Exploring JNJs 2017 Profitability and Financial Guidance(Yahoo Finance)
- 2017-01-26 02:05
Johnson & Johnsons 4Q16 Performance by Business Segment(Marketrealist)
- 2017-01-25 18:37
How Will Eli Lillys Neuroscience Franchise Fare in 4Q16?(Marketrealist)
- 2017-01-23 21:38
How Bristol-Myers Squibbs Oncology Drug Performed in 4Q16(Marketrealist)
- 2017-01-22 21:37
Novartiss 4Q16 Estimates: How Could Sandoz Perform?(Marketrealist)
- 2017-01-19 18:38
Why Johnson & Johnsons 4Q16 Revenues Could Grow(Marketrealist)
- 2017-01-11 22:49
- 2016-12-29 18:38
Exploring GlaxoSmithKlines Business Segments(Marketrealist)
- 2016-12-29 04:05
GlaxoSmithKlines Revenue Trend(Marketrealist)
- 2016-12-08 19:06
How Does Johnson & Johnsons Valuation Compare to Its Peers?(Marketrealist)
- 2016-11-30 19:05
Inside Mercks Business Segment-Wise Performance(Marketrealist)
- 2016-11-29 00:26
Allergans Valuation Compared to Its Peers(Marketrealist)
- 2016-11-22 22:04
Inside Eli Lillys Neuroscience Franchise(Marketrealist)
- 2016-10-28 06:02
What Can We Expect of Pfizers 3Q16 Earnings?(Marketrealist)
- 2016-10-23 22:05
Novartiss 3Q16 Estimates: How Has Sandoz Performed?(Marketrealist)
- 2016-10-23 22:04
Word on the Street about Mercks Animal Health Segment(Marketrealist)
- 2016-10-20 23:04
- 2016-10-18 23:05
Eli Lilly and Co.s 3Q16 Estimates: Neuroscience Franchise(Marketrealist)
- 2016-10-14 02:04
Johnson & Johnsons Pharmaceuticals Segment: 3Q16 Estimates(Marketrealist)
- 2016-09-18 23:04
- 2016-09-15 22:04
Roche Sees Soaring Revenue from Its Bladder Cancer Treatment(Marketrealist)
- 2016-09-09 06:04
What Investors Can Glean from GlaxoSmithKlines Revenue Trend(Marketrealist)
- 2016-08-30 00:19
Is Johnson & Johnsons Valuation High Compared to Its Peers?(Marketrealist)
- 2016-08-26 12:01
- 2016-08-24 23:04
AstraZenecas Recent Product Developments(Marketrealist)
- 2016-08-24 20:04
AstraZeneca and Its Oncology Segments Growth in 2Q16(Marketrealist)
- 2016-08-23 20:04
How Crestor Weakened AstraZenecas CVMD Segment in 2Q16(Marketrealist)
- 2016-08-15 23:04
Remicade Is Driving Down Mercks Immunology Franchise(Marketrealist)
- 2016-08-03 23:04
How Are Eli Lillys New Products Performing?(Marketrealist)
- 2016-08-02 21:04
- 2016-07-31 22:32
What to Expect from Pfizers 2Q16 Earnings(Marketrealist)
- 2016-07-22 01:14
How Did JNJs Pharmaceutical Segment Fare in 2Q16?(Marketrealist)
- 2016-07-22 01:07
Inside Lillys 2Q16 Estimates for Its Neuroscience Franchise(Marketrealist)